Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
Fluvastatin, which is a synthetic 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase inhibitor, its metabolites (M2, M3 and M4) and trolox all inhibited the decrease of apolipoprotein B-100 (apoB) and alpha-tocopherol in a radical reaction of human plasma initiated by Cu2+. The concentrations of fluvastatin, M2, M3, M4 and trolox for 50% inhibition (IC50) of apoB fragmentation were 405, 8.55, 1.75, 305, and 43.4 microM, respectively. The IC50 value of pravastatin, which is another HMG-CoA reductase inhibitor, was 2880 microM, showing that pravastatin is not an effective antioxidant. Although fluvastatin, its metabolites and trolox inhibited the decrease of alpha-tocopherol in a similar manner to that of apoB, pravastatin did not significantly inhibit the decrease of alpha-tocopherol. Since oxidation of low density lipopotein (LDL) is an important step in the initiation and progression of atherosclerosis, fluvastatin may reduce the risk of atherosclerosis not only by lowering plasma cholesterol but also by protecting LDL from oxidation.
Aoki
S
S
Tanabe R&D Service, Co., Ltd., Osaka, Japan. s-aoki@tanabe.co.jp
Ikeda
K
K
Yamamura
M
M
Kojo
S
S
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001055:Apolipoproteins B / Q000097:blood*; D003300:Copper / Q000378:metabolism; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D000077340:Fluvastatin; D005609:Free Radicals; D006801:Humans; D006868:Hydrolysis; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D014810:Vitamin E / Q000097:blood
D000924:Anticholesteremic Agents; D001055:Apolipoproteins B; D005229:Fatty Acids, Monounsaturated; D005609:Free Radicals; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D014810:Vitamin E; D000077340:Fluvastatin; D003300:Copper